Skip to content
Sharism- Lifestyle
Author:
Genmab A/S
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
June 29, 2026
Major Shareholder Announcement
June 16, 2026
Major Shareholder Announcement
May 8, 2026
Genmab Announces Financial Results for the First Quarter of 2026
May 7, 2026
Major Shareholder Announcement
April 14, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
April 14, 2026
Major Shareholder Announcement
April 1, 2026
Major Shareholder Announcement
March 30, 2026